Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nihon Chouzai Co's Debt-to-EBITDA or its related term are showing as below:
NHCZF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.46 Med: 4.36 Max: 8.51
Current: 8.51
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nihon Chouzai Co was 8.51. The lowest was 3.46. And the median was 4.36.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nihon Chouzai Co Debt-to-EBITDA Related Terms
Nihon Chouzai Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nihon Chouzai Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nihon Chouzai Co Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Nihon Chouzai Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nihon Chouzai Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nihon Chouzai Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nihon Chouzai Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.
Nihon Chouzai Co (NHCZF) has a Debt-to-EBITDA of 2.78 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nihon Chouzai Co. This is 36% below median its historical median of 4.36. Over the past decade, Nihon Chouzai Co's Debt-to-EBITDA has ranged from 3.46 to 8.51.
Is Nihon Chouzai Co's Debt-to-EBITDA too high?
Nihon Chouzai Co's current Debt-to-EBITDA of 2.78 is 36% below median its 10-year median of 4.36. Over the past 10 years, this metric has ranged from a low of 3.46 to a high of 8.51. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.21. Nihon Chouzai Co's value of 2.78 is 25.8% above this industry median. Overall, Nihon Chouzai Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Nihon Chouzai Co's Debt-to-EBITDA compare to competitors?
Nihon Chouzai Co's Debt-to-EBITDA of 2.78 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.21. Nihon Chouzai Co's value of 2.78 is 25.8% above this benchmark. Historically, Nihon Chouzai Co's own Debt-to-EBITDA has ranged from 3.46 to 8.51 over the past decade. While the company's 10-year median is 4.36 vs. the industry median of 2.21, Nihon Chouzai Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nihon Chouzai Co's current Debt-to-EBITDA of 2.78 is 25.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nihon Chouzai Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nihon Chouzai Co's current Debt-to-EBITDA is 2.78, which is 36% below median its own 10-year median of 4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nihon Chouzai Co stock overvalued right now?
Nihon Chouzai Co (NHCZF) has a current Debt-to-EBITDA of 2.78. The stock's GF Value™ is $6.38, compared to a current price of $16.02 — trading 151.1% above its estimated fair value. The current Debt-to-EBITDA is 2.78, which is 36% below median its 10-year median of 4.36 and 25.8% above the Healthcare Providers & Services industry median of 2.21. Nihon Chouzai Co's overall GF Score™ is 9/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nihon Chouzai Co (NHCZF), the current Debt-to-EBITDA is 2.78 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nihon Chouzai Co (NHCZF) Overvalued in 2026?
Based on GuruFocus' analysis, Nihon Chouzai Co stock appears to be overvalued.
The current stock price of $16.02 is trading 151.1% above its estimated GF Value™ of $6.38.
Key valuation signals for NHCZF:
Debt-to-EBITDA: 2.78 (36% below median its 10-year median of 4.36)
GF Value™: $6.38 vs. price of $16.02 (151.1% above fair value)
Industry Position: 25.8% above the Healthcare Providers & Services median
No single metric tells the full story. See the NHCZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nihon Chouzai Co Ltd operates in the pharmaceutical industry. The company is organized into segments: Pharmacy, Pharmaceutical Manufacturing and Sales, and Healthcare Staffing Services and operates mainly from Japan. Through its operating segments, the firm manages a chain of pharmacies nationwide, manufactures and sells generic drugs, and provides staffing services that are specialized in pharmacy.
9GF Score
Get the complete analysis for NHCZF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NHCZF has been successfully added to your 
